01:40 , Dec 30, 2016 |  BC Week In Review  |  Company News

Clinical Genomics sales and marketing update

Clinical Genomics launched its Colvera blood-based test in the U.S. to monitor the recurrence of colorectal cancer. Colvera is a PCR-based test that measures two epigenetically modified genes -- hyper-methylated cytosolic branched chain amino-acid transaminase...
07:00 , Aug 4, 2016 |  BC Innovations  |  Targets & Mechanisms

Cereblon ambition

Most anti-cancer strategies aim to block overactive proteins by directly inhibiting their activity, but a growing number of companies are developing ways to tag the proteins for destruction by recruiting the enzymes that shuttle them...
00:58 , Mar 24, 2016 |  BC Extra  |  Financial News

Diagnostics play Clinical Genomics raises $15M

Clinical Genomics Pty. Ltd. (North Ryde, Australia) closed a $15 million series A round led by Australian venture firm OneVentures. This year, Clinical Genomics plans to launch its Gemini test in the U.S. for post-surgical...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

2-Gene Colorectal Cancer Recurrence Test: Clinical trial data

An analysis of 120 patients with known colorectal recurrence status following resection of a primary tumor showed that Clinical Genomics’ 2-Gene Colorectal Cancer Recurrence Test had an overall sensitivity of 63% and specificity of 86%...
08:00 , Jan 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Multiple myeloma (MM) IKAROS family zinc finger 1 (IKZF1; LYF1); IKZF3; cereblon (CRBN) In vitro studies identified...
07:00 , Oct 15, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) ...